Joseph Meletiadis

List of Publications by Year
in descending order

154 papers	8,593 citations	76326 40 h-index	48315 88 g-index
156 all docs	156 docs citations	156 times ranked	7568 citing authors

#	Article	IF	Citations
1	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
2	Infections Caused byScedosporiumspp. Clinical Microbiology Reviews, 2008, 21, 157-197.	13.6	640
3	ESCMIDâ€ and ECMMâ€¡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection, 2014, 20, 5-26.	6.0	547
4	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clinical Microbiology and Infection, 2014, 20, 27-46.	6.0	383
5	Prospective Multicenter International Surveillance of Azole Resistance inAspergillus fumigatus. Emerging Infectious Diseases, 2015, 21, 1041-1044.	4.3	302
6	In vitro susceptibilities of zygomycetes to conventional and new antifungals. Journal of Antimicrobial Chemotherapy, 2003, 51, 45-52.	3.0	299
7	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clinical Microbiology and Infection, 2014, 20, 47-75.	6.0	262
8	Defining Fractional Inhibitory Concentration Index Cutoffs for Additive Interactions Based on Self-Drug Additive Combinations, Monte Carlo Simulation Analysis, and In Vitro - In Vivo Correlation Data for Antifungal Drug Combinations against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2010, 54, 602-609.	3.2	250
9	In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates. Antimicrobial Agents and Chemotherapy, 2003, 47, 106-117.	3.2	234
10	In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 62-68.	3.2	230
11	Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) Methods of In Vitro Susceptibility Testing of Filamentous Fungi and Development of a New Simplified Method. Journal of Clinical Microbiology, 2000, 38, 2949-2954.	3.9	203
12	Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	189
13	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
14	Colorimetric Assay for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2001, 39, 3402-3408.	3.9	148
15	Host-Dependent Patterns of Tissue Injury in Invasive Pulmonary Aspergillosis. American Journal of Clinical Pathology, 2007, 127, 349-355.	0.7	137
16	In Vitro Interaction of Terbinafine with Itraconazole against Clinical Isolates of Scedosporium prolificans. Antimicrobial Agents and Chemotherapy, 2000, 44, 470-472.	3.2	105
17	EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clinical Microbiology and Infection, 2016, 22, 571.e1-571.e4.	6.0	104
18	Assessingin vitrocombinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Medical Mycology, 2005, 43, 133-152.	0.7	99

#	Article	IF	Citations
19	Triazoleâ€Polyene Antagonism in Experimental Invasive Pulmonary Aspergillosis: In Vitro and In Vivo Correlation. Journal of Infectious Diseases, 2006, 194, 1008-1018.	4.0	99
20	In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. Journal of Antimicrobial Chemotherapy, 2015, 70, 470-478.	3.0	96
21	Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis. Antimicrobial Agents and Chemotherapy, 2009, 53, 2382-2391.	3.2	90
22	In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order. Antimicrobial Agents and Chemotherapy, 2015, 59, 7735-7742.	3.2	89
23	Differential Fungicidal Activities of Amphotericin B and Voriconazole against Aspergillus Species Determined by Microbroth Methodology. Antimicrobial Agents and Chemotherapy, 2007, 51, 3329-3337.	3.2	85
24	Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. Antimicrobial Agents and Chemotherapy, 2016, 60, 1097-1105.	3.2	85
25	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infectious Diseases, The, 2021, 21, e375-e386.	9.1	80
26	Comparative In Vitro Pharmacodynamics of Caspofungin, Micafungin, and Anidulafungin against Germinated and Nongerminated Aspergillus Conidia. Antimicrobial Agents and Chemotherapy, 2008, 52, 321-328.	3.2	73
27	Comparison of Spectrophotometric and Visual Readings of NCCLS Method and Evaluation of a Colorimetric Method Based on Reduction of a Soluble Tetrazolium Salt, 2,3-Bis {2-Methoxy-4-Nitro-5-[(Sulfenylamino) Carbonyl]-2H- Tetrazolium-Hydroxide}, for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2001, 39, 4256-4263.	3.9	71
28	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	3.5	66
29	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision. Journal of Antimicrobial Chemotherapy, 2018, 73, 2374-2379.	3.0	65
30	Comparison of the Etest and the Sensititre Colorimetric Methods with the NCCLS Proposed Standard for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2002, 40, 2876-2885.	3.9	59
31	How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates. Clinical Microbiology and Infection, 2019, 25, 681-687.	6.0	59
32	Concentration-Dependent Synergy and Antagonism within a Triple Antifungal Drug Combination against Aspergillus Species: Analysis by a New Response Surface Model. Antimicrobial Agents and Chemotherapy, 2007, 51, 2053-2064.	3.2	57
33	Use of Quantitative Real-Time PCR To Study the Kinetics of Extracellular DNA Released from Candida albicans, with Implications for Diagnosis of Invasive Candidiasis. Journal of Clinical Microbiology, 2006, 44, 143-150.	3.9	53
34	In vitrocombinations of natamycin with voriconazole, itraconazole and micafungin against clinicalFusariumstrains causing keratitis: TableÂ1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 953-955.	3.0	53
35	Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. Journal of Antimicrobial Chemotherapy, 2006, 58, 1168-1176.	3.0	51
36	How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton. Clinical Microbiology and Infection, 2021, 27, 55-60.	6.0	51

#	Article	IF	Citations
37	Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay. Journal of Clinical Microbiology, 2006, 44, 553-560.	3.9	49
38	Concentration-Dependent Effects of Caspofungin on the Metabolic Activity of Aspergillus Species. Antimicrobial Agents and Chemotherapy, 2007, 51, 881-887.	3.2	49
39	Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy, 2008, 63, 343-348.	3.0	46
40	Molecular Epidemiology and Antifungal Susceptibility of Trichophyton Isolates in Greece: Emergence of Terbinafine-Resistant Trichophytonmentagrophytes Type VIII Locally and Globally. Journal of Fungi (Basel, Switzerland), 2021, 7, 419.	3.5	46
41	A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study. Clinical Microbiology and Infection, 2017, 23, 776.e1-776.e5.	6.0	42
42	Comparative Evaluation of Three Commercial Identification Systems Using Common and Rare Bloodstream Yeast Isolates. Journal of Clinical Microbiology, 2011, 49, 2722-2727.	3.9	41
43	Use of Turbidimetric Growth Curves for Early Determination of Antifungal Drug Resistance of Filamentous Fungi. Journal of Clinical Microbiology, 2003, 41, 4718-4725.	3.9	39
44	In Vitro Combination of Isavuconazole with Micafungin or Amphotericin B Deoxycholate against Medically Important Molds. Antimicrobial Agents and Chemotherapy, 2014, 58, 6934-6937.	3.2	39
45	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy, 2017, 72, 3325-3333.	3.0	39
46	Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients. Journal of Medical Microbiology, 2004, 53, 129-134.	1.8	39
47	Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a New In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 403-410.	3.2	38
48	An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics. International Journal of Antimicrobial Agents, 2019, 53, 34-39.	2.5	37
49	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. Journal of Antimicrobial Chemotherapy, 2020, 75, 1807-1819.	3.0	37
50	Epidemiological Cutoff Values for Azoles and Aspergillus fumigatus Based on a Novel Mathematical Approach Incorporating cyp51A Sequence Analysis. Antimicrobial Agents and Chemotherapy, 2012, 56, 2524-2529.	3.2	36
51	Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. Clinical Microbiology Reviews, 2006, 19, 763-787.	13.6	35
52	In Vitro Interaction of Voriconazole and Anidulafungin against Triazole-Resistant Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 796-803.	3.2	35
53	Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	35
54	Study of common functional genetic polymorphisms ofFCGR2A,3Aand3Bgenes and the risk for cryptococcosis in HIV-uninfected patients. Medical Mycology, 2007, 45, 513-518.	0.7	34

#	Article	IF	Citations
55	Amphotericin B- and Voriconazole-Echinocandin Combinations against Aspergillus spp.: Effect of Serum on Inhibitory and Fungicidal Interactions. Antimicrobial Agents and Chemotherapy, 2013, 57, 4656-4663.	3.2	32
56	Isobolographic Analysis of Pharmacodynamic Interactions between Antifungal Agents and Ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2008, 52, 2196-2204.	3.2	31
57	Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. Pharmacogenomics, 2008, 9, 561-584.	1.3	31
58	In Vitro Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	30
59	Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. Journal of Antimicrobial Chemotherapy, 2018, 73, 709-719.	3.0	30
60	Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method. Clinical Microbiology and Infection, 2018, 24, 1200-1204.	6.0	30
61	Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	30
62	The concentration-dependent nature of in vitro amphotericin Bâ€“itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. International Journal of Antimicrobial Agents, 2006, 28, 439-449.	2.5	28
63	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2014, 69, 1611-1619.	3.0	28
64	Rare Invasive Fungal Infections: Epidemiology, Diagnosis and Management. Current Fungal Infection Reports, 2013, 7, 351-360.	2.6	26
65	Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species. Journal of Antimicrobial Chemotherapy, 2006, 59, 230-237.	3.0	25
66	The Strength of Synergistic Interaction between Posaconazole and Caspofungin Depends on the Underlying Azole Resistance Mechanism of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2015, 59, 1738-1744.	3.2	25
67	Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, 3374-3381.	3.0	25
68	Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections. Journal of Antimicrobial Chemotherapy, 2016, 71, 2883-2889.	3.0	23
69	Comparative Evaluation of Sensititre YeastOne and CLSI M38-A2 Reference Method for Antifungal Susceptibility Testing of Aspergillus spp. against Echinocandins. Journal of Clinical Microbiology, 2017, 55, 1714-1719.	3.9	23
70	Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era. Antibiotics, 2022, 11, 771.	3.7	23
71	Characterization and outcome of invasive infections due toPaecilomyces variotii: analysis of patients from the FungiScopeÂ® registry and literature reports. Journal of Antimicrobial Chemotherapy, 2021, 76, 765-774.	3.0	22
72	Inhibitory and Fungicidal Effects of Antifungal Drugs against Aspergillus Species in the Presence of Serum. Antimicrobial Agents and Chemotherapy, 2013, 57, 1625-1631.	3.2	21

#	Article	IF	Citations
73	Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	21
74	Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints. Journal of Antimicrobial Chemotherapy, 2018, 73, 953-961.	3.0	21
75	Composite Survival Index to Compare Virulence Changes in Azole-Resistant Aspergillus fumigatus Clinical Isolates. PLoS ONE, 2013, 8, e72280.	2.5	20
76	Fluconazole Pharmacokinetics in Galleria mellonella Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	20
77	OUP accepted manuscript. Medical Mycology, 2017, 55, 859-868.	0.7	19
78	Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	19
79	Molecular detection and identification of enteroviruses in children admitted to a university hospital in Greece. Molecular and Cellular Probes, 2011, 25, 249-254.	2.1	18
80	Optimization of Polyene-Azole Combination Therapy against Aspergillosis Using an In Vitro Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 3973-3983.	3.2	18
81	Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis. Journal of Thoracic Disease, 2016, 8, E312-E316.	1.4	18
82	Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis. Journal of Antimicrobial Chemotherapy, 2016, 71, 3135-3147.	3.0	18
83	Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections. Journal of Antimicrobial Chemotherapy, 2017, 72, 3366-3373.	3.0	18
84	Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18
85	Spectrophotometric reading of EUCAST antifungal susceptibility testing of Aspergillus fumigatus. Clinical Microbiology and Infection, 2017, 23, 98-103.	6.0	18
86	Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19. Infectious Diseases and Therapy, 2020, 9, 707-713.	4.0	18
87	Treatment of Experimental Candida Sepsis with a Janus Kinase Inhibitor Controls Inflammation and Prolongs Survival. Antimicrobial Agents and Chemotherapy, 2015, 59, 7367-7373.	3.2	17
88	Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital. Infectious Diseases and Therapy, 2021, 10, 1779-1792.	4.0	17
89	Susceptibility Breakpoints for Amphotericin B and Aspergillus Species in an In Vitro Pharmacokinetic-Pharmacodynamic Model Simulating Free-Drug Concentrations in Human Serum. Antimicrobial Agents and Chemotherapy, 2014, 58, 2356-2362.	3.2	16
90	Comparison of Short Versus Prolonged Infusion of Standard Dose ofÂMeropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokineticâ€“Pharmacodynamic Approach. Journal of Pharmaceutical Sciences, 2016, 105, 1513-1518.	3.3	16

#	Article	IF	Citations
91	Genetic diversity and antifungal susceptibility patterns of Aspergillus nidulans complex obtained from clinical and environmental sources. Mycoses, 2020, 63, 78-88.	4.0	16
92	Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients. International Journal of Antimicrobial Agents, 2015, 45, 670-671.	2.5	15
93	Intra- and Interlaboratory Agreement in Assessing theIn VitroActivity of Micafungin against Common and Rare Candida Species with the EUCAST, CLSI, and Etest Methods. Antimicrobial Agents and Chemotherapy, 2016, 60, 6173-6178.	3.2	15
94	Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates. Journal of Antimicrobial Chemotherapy, 2019, 74, 387-394.	3.0	15
95	Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. Journal of Microbiological Methods, 2020, 171, 105861.	1.6	15
96	Activity of Cefepime in Combination with the Novel Î²-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-Î²-Lactamase-Producing Isolates in In Vitro Checkerboard Assays. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	15
97	Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B againstAspergillusspp.. Mycoses, 2010, 53, 239-245.	4.0	14
98	Rhodotorula mucilaginosa associacted meningitis: A subacute entity with high mortality. Case report and review. Medical Mycology Case Reports, 2014, 6, 46-50.	1.3	14
99	MixInYeast: A Multicenter Study on Mixed Yeast Infections. Journal of Fungi (Basel, Switzerland), 2021, 7, 13.	3.5	14
100	Methodological issues related to antifungal drug interaction modelling for filamentous fungi. Reviews in Medical Microbiology, 2002, 13, 101-117.	0.9	13
101	Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins. Antimicrobial Agents and Chemotherapy, 2016, 60, 632-636.	3.2	13
102	Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 988-996.	3.0	13
103	Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales : the Importance of Heteroresistance for Growth Outcome. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
104	In vitroactivity of CAY-1, a saponin fromCapsicum frutescens, againstMicrosporumandTrichophytonspecies. Medical Mycology, 2008, 46, 805-810.	0.7	12
105	EUCAST Testing of Isavuconazole Susceptibility in Aspergillus: Comparison of Results for Inoculum Standardization Using Conidium Counting versus Optical Density. Antimicrobial Agents and Chemotherapy, 2014, 58, 6432-6436.	3.2	12
106	Nationwide surveillance of azole-resistant Aspergillus fumigatus environmental isolates in Greece: detection of pan-azole resistance associated with the TR46/Y121F/T289A cyp51A mutation. Journal of Antimicrobial Chemotherapy, 2020, 75, 3181-3188.	3.0	12
107	Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for In Vitro Antifungal Susceptibility Testing of Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
108	In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates. International Journal of Antimicrobial Agents, 2021, 58, 106440.	2.5	11

#	Article	IF	Citations
109	Pharmacokineticâ€“pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications. Journal of Medical Microbiology, 2016, 65, 211-218.	1.8	11
110	Single-Dose Pharmacodynamics of Amphotericin B against Aspergillus Species in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 3713-3718.	3.2	10
111	Near-Infrared Spectroscopy of the Urinary Bladder during Voiding in Men with Lower Urinary Tract Symptoms: A Preliminary Study. BioMed Research International, 2013, 2013, 1-7.	1.9	10
112	Management of Invasive Fungal Infections in Adult Patients with Hematological Malignancies in Greece during the Financial Crisis: Challenges and Recommendations. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 617	3.6	10
113	A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method. Journal of Antimicrobial Chemotherapy, 2020, 75, 1799-1806.	3.0	10
114	A Prospective Multicenter Cohort Surveillance Study of Invasive Aspergillosis in Patients with Hematologic Malignancies in Greece: Impact of the Revised EORTC/MSGERC 2020 Criteria. Journal of Fungi (Basel, Switzerland), 2021, 7, 27.	3.5	10
115	Relationship between metabolism and biomass of medically important zygomycetes. Medical Mycology, 2006, 44, 429-438.	0.7	9
116	Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model. Journal of Antimicrobial Chemotherapy, 2020, 75, 1879-1888.	3.0	9
117	Synergistic Interaction of the Triple Combination of Amphotericin B, Ciprofloxacin, and Polymorphonuclear Neutrophils against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2011, 55, 5923-5929.	3.2	8
118	Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species. Journal of Antimicrobial Chemotherapy, 2019, 74, 2247-2254.	3.0	8
119	Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility. Clinical Microbiology and Infection, 2020, 26, 1692-1693.	6.0	8
120	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precisionâ€”authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2019, 74, 1761-1762.	3.0	7
121	In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
122	Experimental Candida albicans osteomyelitis: Microbiologic, antigenic, histologic, and 18FDG-PET-CT imaging characteristics in a newly established rabbit model. Medical Mycology, 2019, 57, 1011-1017.	0.7	7
123	Comparative pharmacokinetics of the three echinocandins in ICU patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 2969-2976.	3.0	7
124	Population pharmacokinetics of anidulafungin in ICU patients assessing interâ€•and intrasubject variability. British Journal of Clinical Pharmacology, 2021, 87, 1024-1032.	2.4	7
125	Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline andKlebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2017, 72, 172-180.	3.0	6
126	Exploring the Interplay of Resistance Nodulation Division Efflux Pumps, AmpC and OprD in Antimicrobial Resistance of Burkholderia cepacia Complex in Clinical Isolates. Microbial Drug Resistance, 2020, 26, 1144-1152.	2.0	6

#	Article	IF	Citations
127	In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections. International Journal of Antimicrobial Agents, 2021, 57, 106291.	2.5	6
128	Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6
129	The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6
130	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. Journal of Antimicrobial Chemotherapy, 2022, 77, 1209-1210.	3.0	6
131	Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model. Journal of Antimicrobial Chemotherapy, 2022, 77, 1324-1333.	3.0	6
132	Evaluation of the â€œDip Effectâ€•Phenomenon in Antifungal Susceptibility Testing of Candida spp. against Echinocandins by Use of Gradient Concentration Strips. Journal of Clinical Microbiology, 2015, 53, 3654-3659.	3.9	5
133	Antimicrobial pharmacokinetics and preclinical in vitro models to support optimized treatment approaches for uncomplicated lower urinary tract infections. Expert Review of Anti-Infective Therapy, 2021, 19, 271-295.	4.4	5
134	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authors' response. Journal of Antimicrobial Chemotherapy, 2015, 70, 634-635.	3.0	4
135	Successful therapy of Candida pulcherrima fungemia in a premature newborn with liposomal amphotericin B and micafungin. Medical Mycology Case Reports, 2016, 12, 24-27.	1.3	4
136	Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2019, 75, 140-148.	3.0	4
137	Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?. Journal of Pharmacy and Pharmacology, 2020, 72, 1750-1760.	2.4	4
138	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	4
139	Performance, Correlation and Kinetic Profile of Circulating Serum Fungal Biomarkers of Invasive Aspergillosis in High-Risk Patients with Hematologic Malignancies. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	3.5	4
140	Evaluation of paper gradient concentration strips for antifungal combination testing of Candida spp.. Mycoses, 2015, 58, 679-687.	4.0	3
141	Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators. Journal of Antimicrobial Chemotherapy, 2020, 75, 2573-2581.	3.0	3
142	Oral ribavirin is a highly effective treatment for lower respiratory tract infections due to respiratory syncytial virus or parainfluenza after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 511-513.	2.4	3
143	Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints. Journal of Antimicrobial Chemotherapy, 2021, 76, 3201-3211.	3.0	3
144	Fungal malignant otitis externa caused by Alternaria chlamydospora: first case report. JMM Case Reports, 2015, 2, .	1.3	3

#	Article	IF	Citations
145	Evaluation of the DynamikerÂ® Fungus (1â€“3)-Î²-d-Glucan Assay for the Diagnosis of Invasive Aspergillosis in High-Risk Patients with Hematologic Malignancies. Infectious Diseases and Therapy, 2022, , .	4.0	3
146	Bacterial quantification in tissue homogenates from in vivo pharmacodynamic studies using growth curves. Journal of Medical Microbiology, 2020, 69, 676-684.	1.8	2
147	Early phenotypic detection of fluconazole- and anidulafungin-resistant Candida glabrata isolates. Journal of Antimicrobial Chemotherapy, 2022, 77, 1655-1661.	3.0	2
148	Fungemia due to Moesziomyces aphidis (Pseudozyma aphidis) in a premature neonate. Challenges in species identification and antifungal susceptibility testing of rare yeasts. Journal De Mycologie Medicale, 2022, 32, 101258.	1.5	2
149	A New Marker of Echinocandin Activity in an In Vitro Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of Aspergillus fumigatus Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	1
150	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	1
151	InÂvitro and inÂvivo study on the effect of antifungal agents on hematopoietic cells in mice. Experimental Biology and Medicine, 2015, 240, 1728-1734.	2.4	0
152	Reply to â€œAgar Bioassays for Antifungals in Combination Therapyâ€• Antimicrobial Agents and Chemotherapy, 2016, 60, 5626-5626.	3.2	0
153	Oral Ribavirin with or without the Addition of Immune Globulin for the Treatment of Lower Respiratory Tract Infections Due to Respiratory Syncytial Virus or Parainfluenza in Patients after Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 4498-4498.	1.4	0
154	Expected phenotypes and Expert Rules are Important Complements to Antimicrobial Susceptibility Testing. Clinical Microbiology and Infection, 2022, , .	6.0	0